These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 26352004)
1. GdCl3 suppresses the malignant potential of hepatocellular carcinoma by inhibiting the expression of CD206 in tumor‑associated macrophages. Zhu F; Li X; Jiang Y; Zhu H; Zhang H; Zhang C; Zhao Y; Luo F Oncol Rep; 2015 Nov; 34(5):2643-55. PubMed ID: 26352004 [TBL] [Abstract][Full Text] [Related]
2. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Fan QM; Jing YY; Yu GF; Kou XR; Ye F; Gao L; Li R; Zhao QD; Yang Y; Lu ZH; Wei LX Cancer Lett; 2014 Oct; 352(2):160-8. PubMed ID: 24892648 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of RIP140 suppresses the malignant potential of hepatocellular carcinoma by inhibiting NF‑κB‑mediated alternative polarization of macrophages. Hu YC; Yi ZJ; Zhou Y; Li PZ; Liu ZJ; Duan SG; Gong JP Oncol Rep; 2017 May; 37(5):2971-2979. PubMed ID: 28393222 [TBL] [Abstract][Full Text] [Related]
4. Sunitinib suppresses M2 polarization of macrophages in tumor microenvironment to regulate hepatocellular carcinoma progression. Kong Y; Guo L J Biochem Mol Toxicol; 2023 Jun; 37(6):e23333. PubMed ID: 36797997 [TBL] [Abstract][Full Text] [Related]
5. All-trans retinoic acid inhibits proliferation, migration, invasion and induces differentiation of hepa1-6 cells through reversing EMT in vitro. Cui J; Gong M; He Y; Li Q; He T; Bi Y Int J Oncol; 2016 Jan; 48(1):349-57. PubMed ID: 26548461 [TBL] [Abstract][Full Text] [Related]
6. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation. Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566 [TBL] [Abstract][Full Text] [Related]
7. Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment. Li Q; Ma L; Shen S; Guo Y; Cao Q; Cai X; Feng J; Yan Y; Hu T; Luo S; Zhou L; Peng B; Yang Z; Hua Y J Exp Clin Cancer Res; 2019 Jul; 38(1):303. PubMed ID: 31296243 [TBL] [Abstract][Full Text] [Related]
8. Scorpion inhibits epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma. Yan YQ; Xie J; Wang JF; Shi ZF; Zhang X; Du YP; Zhao XC Exp Biol Med (Maywood); 2018 Apr; 243(7):645-654. PubMed ID: 29486578 [TBL] [Abstract][Full Text] [Related]
9. Ventilagolin Suppresses Migration, Invasion and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells by Downregulating Pim-1. Liu Y; Cheng DH; Lai KD; Su H; Lu GS; Wang L; Lv JH Drug Des Devel Ther; 2021; 15():4885-4899. PubMed ID: 34880599 [TBL] [Abstract][Full Text] [Related]
10. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation. Pang L; Han S; Jiao Y; Jiang S; He X; Li P Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943 [TBL] [Abstract][Full Text] [Related]
11. Norcantharidin inhibits IL-6-induced epithelial‑mesenchymal transition via the JAK2/STAT3/TWIST signaling pathway in hepatocellular carcinoma cells. Gao Y; Li W; Liu R; Guo Q; Li J; Bao Y; Zheng H; Jiang S; Hua B Oncol Rep; 2017 Aug; 38(2):1224-1232. PubMed ID: 28677802 [TBL] [Abstract][Full Text] [Related]
12. MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma. Wei X; Tang C; Lu X; Liu R; Zhou M; He D; Zheng D; Sun C; Wu Z Oncotarget; 2015 Jul; 6(21):18389-405. PubMed ID: 26158762 [TBL] [Abstract][Full Text] [Related]
13. M2-polarized tumor-associated macrophages facilitated migration and epithelial-mesenchymal transition of HCC cells via the TLR4/STAT3 signaling pathway. Yao RR; Li JH; Zhang R; Chen RX; Wang YH World J Surg Oncol; 2018 Jan; 16(1):9. PubMed ID: 29338742 [TBL] [Abstract][Full Text] [Related]
14. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway. Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210 [TBL] [Abstract][Full Text] [Related]
15. Auphen and dibutyryl cAMP suppress growth of hepatocellular carcinoma by regulating expression of aquaporins 3 and 9 in vivo. Peng R; Zhao GX; Li J; Zhang Y; Shen XZ; Wang JY; Sun JY World J Gastroenterol; 2016 Mar; 22(12):3341-54. PubMed ID: 27022216 [TBL] [Abstract][Full Text] [Related]
17. Doxycycline as an inhibitor of the epithelial-to-mesenchymal transition and vasculogenic mimicry in hepatocellular carcinoma. Meng J; Sun B; Zhao X; Zhang D; Zhao X; Gu Q; Dong X; Zhao N; Liu P; Liu Y Mol Cancer Ther; 2014 Dec; 13(12):3107-22. PubMed ID: 25277383 [TBL] [Abstract][Full Text] [Related]
18. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway. Mao J; Wang D; Wang Z; Tian W; Li X; Duan J; Wang Y; Yang H; You L; Cheng Y; Bian J; Chen Z; Yang Y Cancer Lett; 2016 Sep; 380(1):134-43. PubMed ID: 27349166 [TBL] [Abstract][Full Text] [Related]
19. Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway. Chen S; Morine Y; Tokuda K; Yamada S; Saito Y; Nishi M; Ikemoto T; Shimada M Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195849 [TBL] [Abstract][Full Text] [Related]
20. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. Yeung OW; Lo CM; Ling CC; Qi X; Geng W; Li CX; Ng KT; Forbes SJ; Guan XY; Poon RT; Fan ST; Man K J Hepatol; 2015 Mar; 62(3):607-16. PubMed ID: 25450711 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]